Medexus Pharmaceuticals Inc. (CVE:MDP) Revenue Increases 512% Year-over-Year

March 27, 2019 / Portfolio News
SOURCE: Midas Letter Live

March 27, 2019 — Medexus Pharmaceuticals Inc (CVE:MDP) (FRA:P731) CEO Ken d’Entremont provides an overview of the company and highlights its recent financial reporting. The company is the results of the recent amalgamation of three specialty pharmaceutical companies: Pediapharm Inc, Medexus Inc, and Medac Pharma. As d’Entremont explains, the combined entity provides Medexus Pharmaceuticals with a footprint in both Canada and the United States, while expanding its therapeutic expertise to include pediatrics, autoimmune diseases, oncology, and rheumatology. The merger was undertaken to allow the company to rapidly scale. Further, Medexus Pharmaceuticals can now drive revenue while opex stays flat, benefiting from the organic growth of a larger product portfolio. Medexus Pharmaceuticals announced Q3 Fiscal 2019 revenues of $14.4 million, a 512 percent increase year-over-year.

About Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork.  Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-762-2626 ext. 202

Investor Relations (U.S.):

Crescendo Communications, LLC
Tel: +1-212-671-1020

Investor Relations (Canada):

Frank Candido
Direct Financial Strategies and Communication Inc.
Tel: 514-969-5530

Scroll to Top